Stocks · Health care · Pharmaceutical Preparations

Rapport Therapeutics, Inc.

RAPP Clue Score46
United States Fiscal year ends December CIK 0002012593 Results filed 4 Nov 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
James Healy
28 Oct 2026
Director
Buy indirect
6,933
$21.00
$145.59K
James Healy
28 Oct 2026
Director
Buy indirect
3,772
$21.00
$79.21K
James Healy
28 Oct 2026
Director
Buy indirect
6,395
$21.00
$134.30K
James Healy
28 Oct 2026
Director
Buy indirect
952,380
$21.00
$20.00M
Ramiro Sanchez
23 Oct 2026
Director
Buy
3,600
$27.35
$98.48K
John Maraganore
22 Oct 2026
Director
Buy indirect
1,172
$26.92
$31.55K
John Maraganore
22 Oct 2026
Director
Buy indirect
8,239
$26.38
$217.34K
Steven M Paul
22 Oct 2026
Director
Buy indirect
35,714
$27.28
$974.28K
Wendy B. Young
22 Oct 2026
Director
Buy
3,789
$26.39
$99.99K
Paul M Silva
22 Oct 2026
Director
Buy indirect
3,680
$27.08
$99.64K
Abraham Ceesay
21 Oct 2026
Chief Executive Officer
Sold on a plan
2,210
$29.16
$64.45K
Troy A. Ignelzi
21 Oct 2026
Chief Financial Officer
Buy
5,500
$26.10
$143.55K
Abraham Ceesay
7 Oct 2026
Chief Executive Officer
Sold on a plan
1,147
$30.66
$35.17K
Abraham Ceesay
6 Oct 2026
Chief Executive Officer
Sold on a plan
3,375
$32.03
$108.11K

What was left out

Form 4 filings counted 10
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 3
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 1,428,571
History held since 10 Jun 2024